- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07708285
Luvometinib in Combination With Serplulimab for NF2-Related Tumors
A Multicenter, Open-Label Study of Luvometinib in Combination With Serplulimab for the Treatment of NF2-Related Tumors
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
NF2-related schwannomatosis (NF2-SWN) is a rare autosomal dominant disorder characterized by multiple central nervous system tumors, most commonly vestibular schwannomas and meningiomas. Although current treatments such as surgery and radiotherapy can provide disease control, they are not curative and are associated with cumulative neurological morbidity and potential risk of secondary malignancies. There remains a significant unmet need for effective systemic therapies.
This investigator-initiated study is conducted as a substudy within the Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2). The trial evaluates luvometinib in combination with serplulimab in patients with progressive NF2-SWN.
Luvometinib (FCN-159) is a selective MEK1/2 inhibitor with antitumor activity in NF1-associated tumors. Serplulimab (HLX10) is an anti-PD-1 monoclonal antibody approved for multiple solid tumors. Preclinical evidence suggests that MEK inhibition may enhance tumor immunogenicity and synergize with immune checkpoint blockade.
The study aims to assess the safety, tolerability, and preliminary efficacy of this combination in NF2-SWN.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studieorter
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100853
- Chinese PLA General Hospital
-
Kontakt:
- Jun Zhang, MD, PhD
- Telefonnummer: 86+ 10-68182255
- E-post: junzhang301@163.com
-
Beijing, Beijing Municipality, Kina, 100070
- Beijing Tiantan Hospital, Capital Medical University
-
Kontakt:
- Pinan Liu, MD, PhD
- Telefonnummer: 86+ 10-59976611
- E-post: pinanliu@ccmu.edu.cn
-
Beijing, Beijing Municipality, Kina, 100053
- Xuanwu Hospital, Capital Medical University
-
Kontakt:
- Hao Wu, MD, PhD
- Telefonnummer: +86 10-83922345
- E-post: wuhaospine@xwh.ccmu.edu.cn
-
-
Jilin
-
Changchun, Jilin, Kina
- The First Hospital of Jilin University
-
Kontakt:
- Yunqian Li, MD, PhD
- Telefonnummer: 86+ 431-88782222
- E-post: yunqian@jlu.edu.cn
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200080
- Shanghai General Hospital
-
Kontakt:
- Meiqing Lou, MD, PhD
- Telefonnummer: +86 21-63846590
- E-post: loumq68128@hotmail.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Participants must meet the diagnostic criteria for NF2-SWN.
- Presence of at least one measurable target tumor, either vestibular schwannoma or meningioma, with MRI-documented volumetric progression within the past 36 months or clinical symptom progression related to the target tumor.
- The target tumor is considered unsuitable for surgery because of high risk.
- Age >=18 years at the time of screening.
- KPS >=70 or ECOG performance status 0 or 1.
- Adequate organ function based on laboratory tests obtained within 14 days before screening.
- Participant must be able to understand the study and voluntarily sign informed consent.
Exclusion Criteria:
- Pregnant, planning to become pregnant, or currently breastfeeding.
- Participation in another interventional clinical trial within the past 4 weeks, or radiation therapy to target lesion(s) within the past 3 years.
- Severe adverse reactions or intolerable toxicity from prior immune checkpoint inhibitors or MEK inhibitors.
- Concomitant active malignancies, uncontrolled infections, or active autoimmune diseases.
- Severe cardiac, hepatic, renal, gastrointestinal, or ophthalmic diseases.
- Any other factor that may compromise participant safety or study integrity.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Luvometinib + Serplulimab
Subjects will receive luvometinib 8 mg by mouth once daily in combination with serplulimab 4.5 mg/kg intravenously every 3 weeks for up to 12 cycles (28 days per cycle).
|
Oral once daily per predetermined dosage per protocol.
Andra namn:
Intravenous infusion per predetermined dosage per protocol.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Objective Response Rate (ORR) or Hearing Response Rate (HRR)
Tidsram: 12 months
|
Vestibular schwannoma: HRR is defined as WRS improvement exceeding the 95% critical difference from baseline; if baseline WRS is <20%, HRR is defined as a PTA decrease of at least 10 dB. Meningioma: ORR is defined as at least a 20% reduction in target tumor volume from baseline. |
12 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of Adverse Events
Tidsram: From first dose through 30 days after last dose (up to 12 months)
|
Percentage of participants who experience at least one adverse event.
Adverse events will be coded and graded according to NCI CTCAE v5.0.
|
From first dose through 30 days after last dose (up to 12 months)
|
|
Maximum Severity Grade of Adverse Events
Tidsram: From first dose through 30 days after last dose (up to 12 months)
|
Maximum NCI CTCAE v5.0 grade of adverse events experienced by each participant during the reporting period.
|
From first dose through 30 days after last dose (up to 12 months)
|
|
Incidence of Serious Adverse Events
Tidsram: From first dose through 30 days after last dose (up to 12 months)
|
Percentage of participants who experience at least one serious adverse event.
|
From first dose through 30 days after last dose (up to 12 months)
|
|
Incidence of Dose Modifications
Tidsram: From first dose through 30 days after last dose (up to 12 months)
|
Percentage of participants who require at least one dose modification due to an adverse event.
|
From first dose through 30 days after last dose (up to 12 months)
|
|
Incidence of Treatment Interruptions
Tidsram: From first dose through 30 days after last dose.
|
Percentage of participants who require at least one treatment interruption due to an adverse event.
|
From first dose through 30 days after last dose.
|
|
Incidence of Treatment Discontinuations
Tidsram: From first dose through 30 days after last dose.
|
Percentage of participants who discontinue study treatment due to an adverse event.
|
From first dose through 30 days after last dose.
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Sjukdomar i nervsystemet
- Neoplasmer efter plats
- Neoplasmer
- Genetiska sjukdomar, medfödda
- Neoplasmer efter histologisk typ
- Neurodegenerativa sjukdomar
- Otorhinolaryngologiska sjukdomar
- Neuroektodermala tumörer
- Neoplasmer, könsceller och embryonala
- Neoplasmer, nervvävnad
- Neoplasmer i nervsystemet
- Heredodegenerativa störningar, nervsystemet
- Neoplasmer i nervslidan
- Neoplastiska syndrom, ärftligt
- Neurokutana syndrom
- Neoplasmer i det perifera nervsystemet
- Neuroendokrina tumörer
- Öronsjukdomar
- Otorhinolaryngologiska neoplasmer
- Neoplasmer, vaskulär vävnad
- Meningeala neoplasmer
- Neoplasmer i centrala nervsystemet
- Kranial nervsjukdomar
- Neurom
- Neoplasmer i kranialnerven
- Vestibulokochleära nervsjukdomar
- Retrokokleära sjukdomar
- Neurofibrom
- Neurilemma
- Medfödda, ärftliga och neonatala sjukdomar och abnormiteter
- Neurofibromatoser
- Meningiom
- Neurom, akustisk
- Neurofibromatos 2
Andra studie-ID-nummer
- HX-A-2026035
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .